ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $357,721 | -33.6% | 52,222 | +0.5% | 0.00% | -40.0% |
| Q2 2023 | $538,753 | +51.6% | 51,953 | +18.2% | 0.01% | +66.7% |
| Q1 2023 | $355,442 | -50.1% | 43,936 | -2.8% | 0.00% | -50.0% |
| Q4 2022 | $711,979 | -10.6% | 45,205 | -17.5% | 0.01% | +20.0% |
| Q3 2018 | $796,000 | -11.2% | 54,824 | +22.2% | 0.01% | -16.7% |
| Q2 2018 | $896,000 | +23.6% | 44,847 | +8.4% | 0.01% | 0.0% |
| Q1 2018 | $725,000 | -14.0% | 41,369 | +21.1% | 0.01% | 0.0% |
| Q4 2017 | $843,000 | +10.6% | 34,168 | +15.7% | 0.01% | +20.0% |
| Q3 2017 | $762,000 | +16.5% | 29,542 | +22.4% | 0.01% | 0.0% |
| Q2 2017 | $654,000 | -2.1% | 24,129 | +7.7% | 0.01% | 0.0% |
| Q1 2017 | $668,000 | +0.8% | 22,411 | -8.3% | 0.01% | 0.0% |
| Q4 2016 | $663,000 | – | 24,432 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |